Abstract
Here, we present a 59-year-old female with recurrent malignant phyllodes tumor with multiple lung and lymph node metastases who developed a pneumothorax after the administration of pazopanib. The patient received pazopanib as the second-line chemotherapy. After 2.5 months of the therapy, computed tomography (CT) showed a decrease in the sizes and cavitation of lung lesions; however, a left pneumothorax was newly observed. It was difficult to distinguish the pneumothorax by upright chest X-ray. Typical symptom or physical finding of pneumothorax, such as dyspnea, chest pain or decreased breath sound was not observed. As the pneumothorax was small and asymptomatic, the administration of pazopanib was discontinued and follow-up chest X-ray and CT were performed. After 1 week, CT showed an improvement in the pneumothorax. Chemotherapy was switched to eribulin; however, a rapid increase in sizes of lung lesions was observed after the first administration of eribulin, pazopanib was reintroduced. Careful follow-up by chest X-ray and CT was performed and the pneumothorax has not recurred.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Zhang Y, Kleer CG (2016) Phyllodes tumor of the breast: histopathologic features, differential diagnosis, and molecular/genetic updates. Arch Pathol Lab Med 140:665–671
IARC (2019) Publication of the WHO classification of tumours, 5th edition, Volume 2: breast tumours. Available online: https://www.iarc.fr/news-events/who-classification-of-tumours-5th-edition-volume-2-breast-tumours/. Accessed Jun 2022
Tan BY, Acs G, Apple SK et al (2016) Phyllodes tumours of the breast: a consensus review. Histopathology 68:5–21
Rowell MD, Perry RR, Hsiu JG et al (1993) Phyllodes tumors. Am J Surg 165:376–379
Kapiris I, Nasiri N, Healy V et al (2001) Outcome and predictive factors of local recurrence and distant metastases following primary surgical treatment of high-grade malignant phyllodes tumours of the breast. Eur J Surg Oncol 27:723–730
Palassini E, Mir O, Grignani G et al (2022) Systemic treatment in advanced phyllodes tumor of the breast: a multi-institutional European retrospective case-series analyses. Breast Cancer Res Treat 192:603–610
Fede ÂBS, Pereira Souza R, Doi M et al (2021) Malignant phyllodes tumor of the breast: a practice review. Clin Pract 11:205–215
de Roos WK, Kaye P, Dent DM (1999) Factors leading to local recurrence or death after surgical resection of phyllodes tumours of the breast. Br J Surg 86:396–399
Abdalla HM, Sakr MA (2006) Predictive factors of local recurrence and survival following primary surgical treatment of phyllodes tumors of the breast. J Egypt Natl Canc Inst 18:125–133
Parkes A, Wang WL, Patel S et al (2021) Outcomes of systemic therapy in metastatic phyllodes tumor of the breast. Breast Cancer Res Treat 186:871–882
van der Graaf WT, Blay J-Y, Chawla SP et al (2012) Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379:1879–1886
Landrum MJ, Lee JM, Benson M et al (2016) ClinVar: public archive of interpretations of clinically relevant variants. Nucleic Acids Res 44:D862–D868
Tate JG, Bamford S, Jubb HC et al (2019) COSMIC: the catalogue of somatic mutations in cancer. Nucleic Acids Res 47:D941–D947
Kobayashi E, Naito Y, Asano N et al (2019) Interim results of a real-world observational study of eribulin in soft tissue sarcoma including rare subtypes. Jpn J Clin Oncol 49:938–946
Wu H, Li L, Yang J et al (2020) Radiotherapy with apatinib for recurrence of malignant phyllodes tumor of the breast: a case report. Medicine (Baltimore) 99:e18808
Kyriazoglou A, Zagouri F, Dimopoulos MA (2019) Olaratumab administered in two cases of phyllodes tumour of the breast: end of the beginning? ESMO Open 4:e000479
Koukourakis IM, Zygogianni A, Kouloulias V et al (2021) Successful treatment of a locally recurrent and metastatic malignant phyllodes tumor with accelerated radiotherapy and nab-paclitaxel, cisplatin, and liposomal doxorubicin chemotherapy. Chemotherapy 66:82–86
Liu SY, Joseph NM, Ravindranathan A et al (2016) Genomic profiling of malignant phyllodes tumors reveals aberrations in FGFR1 and PI-3 kinase/RAS signaling pathways and provides insights into intratumoral heterogeneity. Mod Pathol 29:1012–1027
Bollag G, Clapp DW, Shih S et al (1996) Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat Genet 12:144–148
Lapinski PE, Kwon S, Lubeck BA et al (2012) RASA1 maintains the lymphatic vasculature in a quiescent functional state in mice. J Clin Invest 122:733–747
Hoag JB, Sherman M, Fasihuddin Q, Lund ME (2010) A comprehensive review of spontaneous pneumothorax complicating sarcoma. Chest 138:510–518
Nakano K, Motoi N, Tomomatsu J et al (2016) Risk factors for pneumothorax in advanced and/or metastatic soft tissue sarcoma patients during pazopanib treatment: a single-institute analysis. BMC Cancer 16:750
Calvetti L, Aprile G (2019) Influence and mechanism of lung cavitation development on antiangiogenic therapy: is cavitation the new caveat? Transl Lung Cancer Res 8:319–322
Caswell DR, Swanton C (2017) The role of tumour heterogeneity and clonal cooperativity in metastasis, immune evasion and clinical outcome. BMC Med 15:133
Aiba H, Kimura H, Yamada S et al (2021) Different patterns of pneumothorax in patients with soft tissue tumors treated with pazopanib: a case series analysis. PLoS ONE 16:e0254866
Acknowledgements
The authors are grateful to the patient for participating in this case report.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
All the authors have no conflict of interest.
Informed consent
Written informed consent was obtained from the patient.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Ohmura, H., Masuda, T., Mimori, K. et al. A case of malignant phyllodes tumor that responded to pazopanib and developed pneumothorax. Int Canc Conf J 12, 31–35 (2023). https://doi.org/10.1007/s13691-022-00572-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13691-022-00572-9